Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$16.15 - $28.93 $102,471 - $183,560
-6,345 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$20.21 - $31.85 $42,016 - $66,216
-2,079 Reduced 24.68%
6,345 $184,000
Q2 2018

Aug 14, 2018

BUY
$19.83 - $24.17 $167,047 - $203,608
8,424 New
8,424 $204,000

About Aptinyx Inc.


  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.